Drug Makers Catch FDA’s Drift, Look to Rid Processes of Variability
This article was originally published in The Gold Sheet
Executive Summary
FDA officials say that drug manufacturers need to have better trending and monitoring programs in place to detect process drift in drug manufacture. They note that many of the controls needed to prevent process drift are already embodied in existing GMP regulations but are underutilized.
You may also be interested in...
FDA Guidance Exempts Legacy Products from Early Stage Process Validation; Endorses Use of PAT
FDA’s final process validation guidance clarifies that legacy products, or products that are currently on the market, will be exempt from early stage process validation. The guidance also endorses the use of process analytical technology for monitoring product quality.
FDA Guidance Exempts Legacy Products from Early Stage Process Validation; Endorses Use of PAT
FDA’s final process validation guidance clarifies that legacy products, or products that are currently on the market, will be exempt from early stage process validation. The guidance also endorses the use of process analytical technology for monitoring product quality.
FDA Proposes to Ease Reporting Burden for Low-Risk CMC Changes
FDA relaxes approach to 40 types of low-risk manufacturing changes.